Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II biweekly gemcitabine + docetaxel first-line trial in elderly patients with advanced non-small cell lung cancer
2007-001474-91Phase 2Active
- Sponsor
- ATHOMAV
- Start
- Mar 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gemcitabine in non-small cell lung cancer (NSCLC), sponsored by ATHOMAV. Primary endpoint: Disease progression. Started Mar 2010; status: active.
02
Drugs
docetaxelgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-001474-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001474-91.